Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 7Rectal Neoplasms 5Colorectal Neoplasms 5Colonic Neoplasms 3Neoplasm Metastasis 2Gastrointestinal Neoplasms 2Recurrence 1Rcctal Cancer 1Neoplasms 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1HER2-positive Locally Advanced Resectable Gastric Cancer 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Carcinoma 1Adenocarcinoma 1Adebrelimab (SHR-1316) 1

Interventions

penpulimab 1lutetium Lu 177 dotatate 1copper dotatate CU-64 1XELOX 1Oxaliplatin 1Lutetium-177 1Lutetium 1IDRX-42 1Drug Therapy 1Colonoscopy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Digestive System Diseases × XELOX × Clear all
NCT05494060 2023-11-07

EXPLORING

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
80 enrolled
Gastrointestinal

Carcinoma, Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡